Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression

Psychiatry Research

Volumn 112, Issue 3, 2002, Pages 251-256

  Zucker, Michal ^a   Aviv, Alex ^b   Shelef, Assaf ^b   Weizman, Abraham ^a   Rehavi, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

3H dihydrotetrabenazine; Depression; Platelet; Vesicular monoamine transporter

Indexed keywords

CARRIER PROTEIN; DIHYDROTETRABENAZINE; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DISEASE DURATION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE MEMBRANE;

ADULT; AGED; BLOOD PLATELETS; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEUROPEPTIDES; RADIOLIGAND ASSAY; RECURRENCE; TETRABENAZINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0037112352     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00223-8     Document Type: Article

References (26)

1. Alvarez J.C., Gluck N., Arnulf I., Quintin P., Leboyer M., Pecquery R., Launay J.M., Perez-Diaz F., Spreux-Varoquaux O. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clinical Pharmacology and Therapeutics. 66:1999;617-624.
2. Berman R.M., Sanacora G., Anand A., Roach L.M., Fasula M.K., Finkelstein C.O., Wachen R.M., Oren D.A., Heninger G.R., Charney D.S. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry. 51:2002;469-473.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 72:1976;248-254.
4. Fava M., Kendler K.S. Major depressive disorder. Neuron. 28:2000;335-341.
5. First M.B., Spitzer R.L., Gibbon M., Williams J. Structured Clinical Interview for DMS-IV Axis I Disorders (SCID), Clinical Version: User's Guide. 1996;American Psychiatric Press, Washington, DC.
6. Fon E.A., Pothos E.N., Sun B.-C., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron. 19:1997;1271-1283.
7. Guy W. Clinical Global Impression Severity Scale. ECDEU Assessment Manual for Psychopharmacology. 1976;National Institute of Mental Health, Bethesda, Maryland.
8. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 23:1960;56-62.
9. Kjeldsen S.E., Gjesdal K., Leren P., Eide I.K. Decreased platelet-free dopamine and unchanged noradrenaline inessential-hypertension. Thrombosis Haemostasis. 60:1988;251-254.
10. Koslow S.H., Maas J.W., Bowden C.L., Davis J.M., Hanin I., Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. Archives of General Psychiatry. 40:1983;999-1010.
11. Lake C.R., Pickar D., Ziegler M.G., Lipper S., Slater S., Murphy D.L. High plasma norepinephrine levels in patients with major affective disorder. American Journal of Psychiatry. 139:1982;1315-1318.
12. Lederbogen F., Gilles M., Maras A., Hamann B., Colla M., Heuser I., Deuschle M. Increased platelet aggregability in major depression? Psychiatry Research. 102:2001;255-261.
13. Naudon L., Leroux-Nicollet I., Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neuroscience Letter. 173:1994;1-4.
14. Paul S.M., Rehavi M., Skolnick P., Ballenger J.C., Goodwin F.K. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin 'transporter'. Archives of General Psychiatry. 38:1981;1315-1317.
15. Reimer R.J., Fon E.A., Edwards R.H. Vesicular neurotransmitter transport and the presynaptic regulation of quantal size. Current Opinion in Neurobiology. 8:1998;405-412.
16. Schrieber W., Krieg J.C., Eichhorn T. Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition (letter). Journal of Neurology, Neurosurgery and Psychiatry. 67:1999;550.
17. Smith C.C.T., Betteridge D.J. Platelet noradrenaline and adrenaline efflux in hypercholestrolaemia: studies in platelet-rich plasma. Platelets. 11:2000;395-400.
18. Stahl S.M., Meltzer H.Y. The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. Experimental Neurology. 59:1978;1-15.
19. Staley J.K., Malison R.T., Innis R.B. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biological Psychiatry. 44:1998;534-549.
20. Stitzel R.E. The biological fate of reserpine. Pharmacological Reviews. 28:1977;179-205.
21. Stockmeier C.A., Dilley G.E., Shapiro L.A., Overholser J.C., Thompson P.A. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology. 16:1997;162-173.
22. Van der Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. European Journal of Pharmacology. 294:1995;577-583.
23. Zubieta J.K., Huguelet P., Ohl L.E., Koeppe R.A., Kilbourn M.R., Carr J.M., Giordani B.J., Frey K.A. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. American Journal of Psychiatry. 157:2000;1619-1628.
24. Zubieta J.K., Taylor S.F., Huguelet P., Koeppe R.A., Kilbourn M.R., Frey K.A. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia and healthy subjects. Biological Psychiatry. 49:2001;110-116.
25. Zucker M., Weizman A., Harel D., Rehavi M. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat substantia nigra and prefrontal cortex induced by psychotropic drugs. Neuropsychobiology. 44:2001;187-191.
26. 3H]TBZOH binding to human platelet vesicular monoamine transporter. Life Sciences. 69:2001;2311-2317.